Bisphosphonates reduce bone resorption by shortening the lifespan of osteoclast cells and
inhibiting their activity. Oral bisphosphonates must be taken on an empty stomach while the …

Denosumab (formerly AMG 162) is a fully human monoclonal antibody with a high affinity
and specificity for receptor activator of nuclear factor-κB ligand, a cytokine member of the …

Postmenopausal osteoporosis is a major concern to public health. Fractures are the major
clinical consequence of osteoporosis and are associated with substantial morbidity …

Introduction: Low trauma fractures due to osteoporosis are a major health concern
worldwide. Despite the availability of many therapeutic compounds to reduce fracture risk …

Denosumab, a fully human monoclonal antibody to RANK ligand [RANK-L]) was approved
for the treatment of postmenopausal osteoporosis in June 2010, and is highly effective in …

Denosumab is a fully human monoclonal antibody that inhibits the formation, function and
survival of osteoclasts, preventing the interaction of tumor necrosis factor ligand superfamily …

Agent for osteoporosis Osteoporosis is characterized by decreased bone mass and an
increased risk of fracture, most often at the spine, hip, and wrist. Because of the reduction in …

Introduction: Bone strength determinants such as bone mineral density and bone quality
parameters are determined by life-long remodeling of skeletal tissue. Denosumab is a fully …

Transitioning postmenopausal women with osteoporosis from a bisphosphonate to
denosumab appears to be safe and more effective at improving BMD than continuing …

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal
women worldwide. Treatment of osteoporosis has been ubiquitous throughout the …